HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

ghted that marketing authorisation for VELCADE has been granted, as it is the first major advance for patients with multiple myeloma in more than a decade, and marks the company's commitment to Oncology." said Ken Watters, European Medical Director, Ortho Biotech.

"The approval of VELCADE today brings renewed hope to thousands of European multiple myeloma patients and their families" said Eric Low, Executive Director, International Myeloma Foundation (UK). "The multiple myeloma advocacy community has campaigned tirelessly over the years for cutting edge treatments such as VELCADE to be made available to patients, this is a very proud day", he continued.

The findings of a pre-specified interim analysis from an ongoing phase III trial which compared VELCADE to dexamethasone in refractory multiple myeloma patients found a statistically significant improvement in time to disease progression the primary endpoint of the trial in patients receiving VELCADE compared to patients receiving high-dose dexamethasone. Patients in the control arm of the trial were given the opportunity to switch to VELCADE as soon as possible based on an interim analysis that found a statistically significant improvement in TTP in patients receiving VELCADE compared to patients receiving dexamethasone.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. There are approximately 50 ongoing clinical trials (in Europe and the US) investigating the potential of VELCADE in all stages of multiple myeloma and other cancers.

A single licence has been granted to market VELCADE in the 15 member states of the EU, plus Norway and Iceland. In addition it will be available in the 10 accession countries.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Ph
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:7/29/2015)... ... , ... This year, the threat of flooding is higher in many areas ... water, mold is not far behind. Paul Davis, a leading provider of property restoration ... damage. Paul Davis is regularly called on to handle these types of emergencies, although ...
(Date:7/29/2015)... ... July 29, 2015 , ... CrossFit 269, offering a nationally ... Kalamazoo Strength & Conditioning. , The name change coincides with the release of ... training center over the past three years,” according to Jack Kelly, the center’s ...
(Date:7/29/2015)... ... July 29, 2015 , ... Orthopedic surgeons at Lourdes Medical Center of ... Rotator Cuff System, a new implant to treat a common source of shoulder pain ... regeneration of additional tendon tissue, which could allow for faster healing and a decreased ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal beauty ... of looking good on the big day. Every bride wants to look and feel beautiful, ... , According to a recent study by the American Academy of ...
(Date:7/29/2015)... ... July 29, 2015 , ... Fastline Publications, ... of 2015 on RFD-TV. , Fastline is dedicated to quality agricultural advertising, both ... contains the largest and freshest searchable agriculture equipment database in the world. The ...
Breaking Medicine News(10 mins):Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 2Health News:Paul Davis Offers Tips to Minimize Property Damage and Health Risks This Flood Season 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 2Health News:Lourdes Orthopedics First in NJ to Offer Bioinductive Implant for Rotator Cuff Repair 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3Health News:Fastline Publications to Partner with American Farmer in Upcoming Episode Airing on RFD-TV 2
(Date:7/29/2015)... Calif. , July 29, 2015 /PRNewswire/ ... or the "Company"), the leading provider of ... sciences industry, serving markets including immunotherapies, stem ... manufacturers, animal health, and reproductive medicine, announced ... sale of common stock and warrants (the "Units") under ...
(Date:7/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/sxwk89/3d_metrology ) ... Market by Product (CMM, ODS, and VMM), Application (Automotive, ... (North America, Europe, APAC, RoW) - Global Forecast to ... The 3D metrology market was valued at $1,456.7 ... a rate of 7.11% during the forecast period. ...
(Date:7/29/2015)... DIEGO , July 29, 2015  ViaCyte, Inc., a privately-held ... for the treatment of diabetes in clinical trials, today announced the ... STEP ONE, or S afety, T olerability, and ... One Diabetes.  The new site, which is the first in ... Alberta Hospitals in Edmonton , Alberta.  ...
Breaking Medicine Technology:Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Global 3D Metrology Market 2015-2020: Products (CMM, ODS, and VMM) & Applications (Automotive, Aerospace, Energy & Power, Medical and Electronics) 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4
Cached News: